Mononucleosis diagnosis summary

Revision as of 16:11, 19 December 2012 by Maheep Sangha (talk | contribs)
Jump to navigation Jump to search

Mononucleosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Causes

Differentiating Mononucleosis from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mononucleosis diagnosis summary On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mononucleosis diagnosis summary

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mononucleosis diagnosis summary

CDC on Mononucleosis diagnosis summary

Mononucleosis diagnosis summary in the news

Blogs on Mononucleosis diagnosis summary

Directions to Hospitals Treating Mononucleosis

Risk calculators and risk factors for Mononucleosis diagnosis summary

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]

Overview

Diagnosis Summary: Based on the Stage of Infection

Primary Infection

  • Primary EBV infection is indicated if IgM antibody to the viral capsid antigen is present and antibody to EBV nuclear antigen (EBNA), is absent.
  • A rising or high IgG antibody to the viral capsid antigen and negative antibody to EBV nuclear antigen after at least 4 weeks of illness is also strongly suggestive of primary infection.
  • In addition, 80% of patients with active EBV infection produce antibody to early antigen.

Past Infection

  • If antibodies to both the viral capsid antigen and EBV nuclear antigen are present, then past infection (from 4 to 6 months to years earlier) is indicated.
  • Since 95% of adults have been infected with EBV, most adults will show antibodies to EBV from infection years earlier.
  • High or elevated antibody levels may be present for years and are not diagnostic of recent infection.

Reactivation

  • In the presence of antibodies to EBV nuclear antigen, an elevation of antibodies to early antigen suggests reactivation.
  • However, when EBV antibody to the early antigen test is present, this result does not automatically indicate that a patient's current medical condition is caused by EBV.
  • A number of healthy people with no symptoms have antibodies to the EBV early antigen for years after their initial EBV infection. Many times reactivation occurs subclinically.

Chronic EBV Infection

  • Reliable laboratory evidence for continued active EBV infection is very seldom found in patients who have been ill for more than 4 months.
  • When the illness lasts more than 6 months, it should be investigated to see if other causes of chronic illness or chronic fatigue syndrome (CFS) are present.
Antibody (AB) Time of appearance Persistence % Patients present
Viral capsid antigen-IgM (VCA-IgM) At clinical presentation 1-3 months 100%
Viral capsid antigen-IgG (VCA-IgG) At clinical presentation Lifelong 100%
Early antigen-IgG (EA IgG) Peak 3-4 weeks after onset 3-6 months 70%
EBV nuclear antigen-IgG (EBNA IgG) 6-12 weeks after onset Lifelong 100%

Resources

References


Template:WikiDoc Sources